Laboratory parameters during the course of imatinib treatment and at the time of molecular relapse
| Pt no. . | Eosinophils/mm3 . | Serum B12, ng/mL . | Serum tryptase, ng/mL . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before . | After . | Disc . | Relapse . | Before . | After . | Disc . | Relapse . | Before . | After . | Disc . | Relapse . | |
| 1 | 5993 | 107 | NA | 150 | 5488 | 761 | NA | 269 | 22.6 | 2.35 | NA | 3.35 |
| 2 | 1906 | 109 | 157 | 224 | 1385 | 440 | 322 | 279 | 17.9 | 1.49 | 2.05 | 2.86 |
| 3 | 8352 | 157 | 88 | 155 | 6995 | 729 | 356 | 356 | 19 | <1 | <1 | 1.21 |
| 4 | 16228 | 68 | 57 | 147 | 7085 | 570 | 337 | 338 | 29.4 | 2.3 | 4.08 | 8.76 |
| 5 | 4027 | 71 | 96 | 90 | 1443 | 906 | 924 | 1301 | 14.3 | 2.08 | 2.83 | 2.79 |
| 6 | 43 | 107 | NA | NA | 3889 | 926 | NA | NA | 13.7 | 4.11 | NA | NA |
| 7 | 758 | 1376 | NA | NA | 1192 | 882 | NA | NA | 49.5 | 3.35 | NA | NA |
| Pt no. . | Eosinophils/mm3 . | Serum B12, ng/mL . | Serum tryptase, ng/mL . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before . | After . | Disc . | Relapse . | Before . | After . | Disc . | Relapse . | Before . | After . | Disc . | Relapse . | |
| 1 | 5993 | 107 | NA | 150 | 5488 | 761 | NA | 269 | 22.6 | 2.35 | NA | 3.35 |
| 2 | 1906 | 109 | 157 | 224 | 1385 | 440 | 322 | 279 | 17.9 | 1.49 | 2.05 | 2.86 |
| 3 | 8352 | 157 | 88 | 155 | 6995 | 729 | 356 | 356 | 19 | <1 | <1 | 1.21 |
| 4 | 16228 | 68 | 57 | 147 | 7085 | 570 | 337 | 338 | 29.4 | 2.3 | 4.08 | 8.76 |
| 5 | 4027 | 71 | 96 | 90 | 1443 | 906 | 924 | 1301 | 14.3 | 2.08 | 2.83 | 2.79 |
| 6 | 43 | 107 | NA | NA | 3889 | 926 | NA | NA | 13.7 | 4.11 | NA | NA |
| 7 | 758 | 1376 | NA | NA | 1192 | 882 | NA | NA | 49.5 | 3.35 | NA | NA |
Before indicates before treatment; after, 1 month after treatment; disc, at the time treatment was discontinued; relapse, at the time of molecular relapse; NA, not applicable.